Anne J Novak

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6178044/publications.pdf

Version: 2024-02-01

124 papers	5,308 citations	147801 31 h-index	88630 70 g-index
125 all docs	125 docs citations	125 times ranked	8651 citing authors

#	Article	IF	Citations
1	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 2018, 24, 679-690.	30.7	1,224
2	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3879-3884.	7.1	853
3	Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood, 2004, 103, 689-694.	1.4	474
4	Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood, 2004, 104, 2247-2253.	1.4	216
5	Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood, 2002, 100, 2973-2979.	1.4	213
6	CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25â^' T cells. Blood, 2007, 110, 2537-2544.	1.4	181
7	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238.	21.4	147
8	Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. Oncotarget, 2017, 8, 61425-61439.	1.8	146
9	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. Journal of Experimental Medicine, 2010, 207, 2569-2579.	8.5	96
10	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471.	6.2	96
11	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933.	12.8	94
12	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. Clinical Cancer Research, 2014, 20, 2862-2872.	7.0	86
13	Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. Journal of Clinical Oncology, 2006, 24, 983-987.	1.6	85
14	Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood, 2011, 118, 5540-5549.	1.4	72
15	TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Antiâ€“PD-1 Response in Follicular Lymphoma. Clinical Cancer Research, 2020, 26, 5217-5231.	7.0	67
16	Genetic Variation in B-Cellâ€“Activating Factor Is Associated with an Increased Risk of Developing B-Cell Nonâ€“Hodgkin Lymphoma. Cancer Research, 2009, 69, 4217-4224.	0.9	59
17	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751.	12.8	58
18	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. International Journal of Epidemiology, 2017, 46, 1753-1754i.	1.9	57

#	Article	IF	Citations
19	MYD88 mutation status does not impact overall survival in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
20	Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Reports, 2019, 26, 2178-2193.e3.	6.4	57
21	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer Journal, 2019, 9, 22.	6.2	54
22	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinaseâ€“regulated mammalian target of rapamycin activation. Blood, 2009, 113, 5206-5216.	1.4	46
23	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. Bioinformatics, 2014, 30, 2678-2680.	4.1	43
24	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
25	Establishment and characterization of a novel WaldenstrÃ¶m macroglobulinemia cell line, MWCL-1. Blood, 2011, 117, e190-e197.	1.4	40
26	IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. Blood, 2012, 120, 3774-3782.	1.4	40
27	Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Advances, 2018, 2, 1985-1997.	5.2	39
28	Elevated pretreatment serum levels of interferonâ€inducible proteinâ€10 (CXCL10) predict disease relapse and prognosis in diffuse large Bâ€cell lymphoma patients. American Journal of Hematology, 2012, 87, 865-869.	4.1	37
29	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
30	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97.	6.2	36
31	SIRPÎ± expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. Blood Cancer Journal, 2019, 9, 84.	6.2	35
32	RVboost: RNA-seq variants prioritization using a boosting method. Bioinformatics, 2014, 30, 3414-3416.	4.1	34
33	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
34	Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	1.3	28
35	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	7.2	28
36	Lack of intrafollicular memory CD4â€‰+â€‰T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	6.2	27

#	Article	IF	Citations
37	Associations between elevated preâ€treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. American Journal of Hematology, 2017, 92, 752-758.	4.1	23
38	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. British Journal of Haematology, 2018, 182, 644-653.	2.5	20
39	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in nonâ€follicular indolent Bâ€cell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	4.1	19
40	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer Journal, 2020, 10, 117.	6.2	18
41	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	1.4	17
42	Non-Hodgkin Lymphoma B-Cells Induce Intratumoral CD4+CD25â˜ T Cells To Express Foxp3 and Gain Regulatory Function.. Blood, 2006, 108, 1724-1724.	1.4	17
43	Expression of KLRG1 and CD127 defines distinct CD8⁺ subsets that differentially impact patient outcome in follicular lymphoma. , 2021, 9, e002662.		16
44	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187.	2.7	15
45	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182.	12.8	15
46	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. Blood, 2011, 118, 1570-1570.	1.4	15
47	Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. Redox Biology, 2020, 36, 101657.	9.0	12
48	First report of MYD88^{L265P} somatic mutation in IgM-associated light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 42-43.	3.0	10
49	FCGR3A/2A polymorphisms and diffuse large Bâ€cell lymphoma outcome treated with immunochemotherapy: a metaâ€analysis on 1134 patients from two prospective cohorts. Hematological Oncology, 2017, 35, 447-455.	1.7	9
50	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1061-1070.	2.5	8
51	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	1.4	7
52	Role of B-Lymphocyte Stimulator (BLyS) in Waldenstromâ€™s Macroglobulinemia.. Blood, 2005, 106, 601-601.	1.4	7
53	The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 andtim-3 Expression. Blood, 2015, 126, 2661-2661.	1.4	7
54	B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells. Leukemia and Lymphoma, 2014, 55, 1884-1892.	1.3	6

#	Article	IF	Citations
55	Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.. Blood, 2005, 106, 1495-1495.	1.4	6
56	Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene. Leukemia and Lymphoma, 2017, 58, 2247-2250.	1.3	5
57	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. Clinical Cancer Research, 2020, 26, 5759-5771.	7.0	5
58	Interactions Between PD-1 and PD-L1 and PD-L2 Promote Malignant B-Cell Growth in Waldenstrom Macroglobulinemia. Blood, 2013, 122, 4334-4334.	1.4	5
59	Chronic lymphocytic leukemia B-cell-derived TNFÎ± impairs bone marrow myelopoiesis. IScience, 2021, 24, 101994.	4.1	4
60	Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 603-603.	1.4	4
61	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. Blood, 2009, 114, 440-440.	1.4	4
62	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 308-315.	1.3	3
63	Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.. Blood, 2005, 106, 2411-2411.	1.4	3
64	Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.. Blood, 2008, 112, 2251-2251.	1.4	3
65	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. Blood, 2012, 120, 2699-2699.	1.4	3
66	Role of CCL5 and Interleukin-6 in the Biology of Waldenstrol̀m Macroglobulinemia.. Blood, 2007, 110, 688-688.	1.4	2
67	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. Blood, 2013, 122, 499-499.	1.4	2
68	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	1.4	2
69	Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma. Clinical Cancer Research, 2022, 28, 4322-4335.	7.0	2
70	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances, 2022, 6, 5210-5221.	5.2	2
71	Phase 1 Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.. Blood, 2006, 108, 2722-2722.	1.4	1
72	Altered Expression of Immune Checkpoint Molecules Including Programmed Cell Death-1 (PD-1) and Its Ligands PD-L1/PD-L2 in Waldenstrom's Macroglobulinemia. Blood, 2016, 128, 1772-1772.	1.4	1

#	Article	IF	Citations
73	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. Blood, 2016, 128, 5299-5299.	1.4	1
74	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstromâ€™s Macroglobulinemia.. Blood, 2004, 104, 2291-2291.	1.4	1
75	APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.. Blood, 2007, 110, 3585-3585.	1.4	1
76	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. Blood, 2009, 114, 925-925.	1.4	1
77	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2009, 114, 3933-3933.	1.4	1
78	Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.. Blood, 2009, 114, 3927-3927.	1.4	1
79	Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenstroì`m Macroglobulinemia.. Blood, 2009, 114, 1691-1691.	1.4	1
80	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2010, 116, 991-991.	1.4	1
81	A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. Blood, 2010, 116, 143-143.	1.4	1
82	TGF-Î² Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). Blood, 2011, 118, 1586-1586.	1.4	1
83	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. Blood, 2011, 118, 429-429.	1.4	1
84	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	1.4	1
85	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 622-622.	1.4	1
86	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
87	Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile.. Journal of Clinical Oncology, 2020, 38, 8052-8052.	1.6	1
88	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	2.5	1
89	APRIL Promotes Survival and Proliferation of T Cells: Implications for T-Cell Lymphoma.. Blood, 2004, 104, 2652-2652.	1.4	0
90	Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms.. Blood, 2004, 104, 964-964.	1.4	0

#	Article	IF	Citations
91	Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.. Blood, 2004, 104, 1397-1397.	1.4	0
92	Intratumoral CD4+CD25+ Regulatory T-Cell-Mediated Suppression of Infiltrating CD4+ T-Cells in B-Cell Non-Hodgkin Lymphoma.. Blood, 2005, 106, 3312-3312.	1.4	0
93	Intratumoral Treg Cells Completely Inhibit the Induction and Function of Tumor-Infiltrating CD8+ T-Cells in B-Cell NHL.. Blood, 2005, 106, 3311-3311.	1.4	0
94	Malignant B Cells Skew the Balance between Treg Cell and TH17 Cell Differentiation in B-Cell Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 1347-1347.	1.4	0
95	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. Blood, 2010, 116, 1999-1999.	1.4	0
96	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. Blood, 2010, 116, 468-468.	1.4	0
97	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. Blood, 2010, 116, 3115-3115.	1.4	0
98	IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 770-770.	1.4	0
99	A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. Blood, 2011, 118, 2642-2642.	1.4	0
100	Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.. Blood, 2012, 120, 2688-2688.	1.4	0
101	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	1.4	0
102	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	1.4	0
103	IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia. Blood, 2012, 120, 1554-1554.	1.4	0
104	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. Blood, 2012, 120, 2702-2702.	1.4	0
105	An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.. Journal of Clinical Oncology, 2014, 32, e22171-e22171.	1.6	0
106	Presence and function of CD14+CD16-HLADRlow monocytes in the peripheral blood of patients with Î'-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2014, 32, e19539-e19539.	1.6	0
107	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 131-131.	1.4	0
108	Signal-Regulatory Protein-Î± (SIRP-Î±) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. Blood, 2016, 128, 2515-2515.	1.4	0

#	Article	IF	Citations
109	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	1.4	0
110	Isogenic Loss of TNFAIP3 in Waldenstrom Macroglobulinemia Enhances MYD88L265P-Driven Signaling. Blood, 2016, 128, 4100-4100.	1.4	0
111	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). Blood, 2018, 132, 4138-4138.	1.4	0
112	A Role for TNF-Î± in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. Blood, 2019, 134, 4276-4276.	1.4	0
113	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	1.4	0
114	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. Blood, 2019, 134, 2764-2764.	1.4	0
115	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	1.4	0
116	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	1.4	0
117	Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. Blood, 2019, 134, 2790-2790.	1.4	0
118	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	1.4	0
119	T-Cell Phenotype Varies in Distinct Tumor Microenvironments and CD57 + T FH Cells Are Associated with Disease Progression and Inferior Survival in Follicular Lymphoma. Blood, 2021, 138, 3522-3522.	1.4	0
120	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1439-1439.	1.4	0
121	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. Blood, 2021, 138, 808-808.	1.4	0
122	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	1.4	0
123	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	1.4	0
124	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. Blood, 2020, 136, 17-18.	1.4	0